VIVUS LLC

VIVUS BV, a subsidiary of VIVUS LLC, today announced the availability of QSIVA (phentermine and topiramate modified-release) in Sweden, Denmark, Finland, Iceland, Norway, and Poland, making QSIVA accessible to patients with overweight or obesity who could benefit from weight loss. Read the press release here: https://lnkd.in/ejJx37t8 #obesitymedicine #treatingobesity #vivusllc #vivusbv Important Safety Information for QSYMIA / QSIVA QSYMIA is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSYMIA. QSIVA is contraindicated in pregnancy and in women of childbearing potential who are not using effective methods of contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSIVA. QSYMIA / QSIVA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSYMIA / QSIVA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSYMIA / QSIVA. If a patient becomes pregnant while taking QSYMIA / QSIVA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. The most common adverse reactions to QSYMIA reported in the pediatric clinical trial included depression, dizziness, arthralgia, pyrexia, influenza, and ligament sprain. The most common adverse reactions to QSYMIA in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth. The most common adverse reactions to QSIVA in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth. For information on QSIVA, please visit QSIVA.eu. For information about QSYMIA, please visit QSYMIA.com.

Sept 29th is World Heart Day — a global event bringing people together to increase awareness, engage communities, and advocate for universal access to cardiovascular disease prevention, detection, and treatment. This VIVUS-sponsored USA Today article highlights a VIVUS prescription weight-management medicine, its efficacy and impact on cardiovascular disease risk factors in adults and adolescents with obesity. People with obesity are at greater risk for health challenges like coronary artery disease, which is a buildup of plaque in the arteries, as well as diabetes, high blood pressure, cancer, stroke, and more (Source: Centers for Disease Control and Prevention). Read the USA Today article here: https://lnkd.in/eYxH6s8H To learn more about World Heart Day visit: https://lnkd.in/d2R_NjZ VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #whd #worldheartday #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

People with diabetes are at higher risk for exocrine pancreatic insufficiency, which affects properly digesting and absorbing nutrients from food. The good news is, the condition is treatable. This article from the diaTribe Foundation describes what EPI is, its causes, and why it is frequently underdiagnosed in people with diabetes. Read the article here: https://lnkd.in/eupHJ4W9 The mission of the diaTribe Foundation is to help people with diabetes and prediabetes, and to advocate for action. The organization attempts to help people with diabetes live happier, healthier, and more hopeful lives through their diaTribe publication, Learn, which reaches over 6 million people each year. VIVUS is proud to work with gastroenterology specialists and organizations to build awareness of EPI (Exocrine Pancreatic Insufficiency) and provide treatment options to help patients manage this lifelong condition. Please visit VIVUS.com to learn more. #treatingEPI #ExocrinePancreaticInsufficiency #vivusllc

VIVUS is excited to be exhibiting at the North American Cystic Fibrosis Conference, September 26 - 28, 2024 in Boston, Massachusetts. NACFC provides a collaborative and educational forum for all CF professionals. The educational elements of the meeting program are targeted to physicians, nurses, research scientists, respiratory therapists, physical therapists, nutritionists, social workers, and pharmacists. Please visit the VIVUS booth 716 — we look forward to seeing you there. To learn more visit: https://lnkd.in/guxAenZ VIVUS is committed to working with gastroenterology professionals and associations in order to build awareness of EPI (Exocrine Pancreatic Insufficiency) and provide treatment options to help patients manage this lifelong condition. Visit VIVUS.com to learn more about our work in this area. #NACFC2024 #treatingEPI #ExocrinePancreaticInsufficiency #vivusllc

In this LinkedIn article, John Amos, the Chief Executive Officer of VIVUS, discusses the importance of developing an obesity action plan that includes trusted medications. As the article notes, with the right tools and support system, managing and sustaining weight loss can be a transformational journey for patients suffering from obesity. Read the article here: https://lnkd.in/exP-5QTX VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

In this LinkedIn article, John Amos, the Chief Executive Officer of VIVUS, discusses the importance of developing an obesity action plan that includes trusted medications. As the article notes, with the right tools and support system, managing and sustaining weight loss can be a transformational journey for patients suffering from obesity. Read the article here: https://lnkd.in/exP-5QTX VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

New research published by the Lancet seeks to establish the prevalence and predictors of Exocrine Pancreatic insufficiency (EPI) following acute pancreatitis (AP). In this prospective, multicentre, longitudinal cohort study, EPI was present in over one third of prospectively assessed adult patients at 12 months after a case of acute pancreatitis. Read the open access research at the Lancet: https://lnkd.in/eW26Sb9e VIVUS is committed to working with gastroenterology professionals and associations in order to build awareness of EPI (Exocrine Pancreatic Insufficiency) and provide treatment options to help patients manage this lifelong condition. To learn more about our work in this area, please visit VIVUS.com. #treatingEPI #ExocrinePancreaticInsufficiency #vivusllc

Every September, The Centers for Disease Control and Prevention (CDC) recognizes National Childhood Obesity Awareness Month as a time to raise awareness about preventing childhood obesity. Childhood obesity is a complex disease with many contributing factors, including genetics, eating patterns, physical activity levels, and sleep routines. One in 5 children in the United States are obese. Compared to children with healthy weight, children with obesity are at a higher risk for asthma, sleep apnea, bone and joint problems, type 2 diabetes, and other health issues. Although there is no one solution, there are many ways parents and caregivers can help children have a healthy weight and set up lifelong healthy habits. Read the CDC's article "Preventing Childhood Obesity: 6 Things Families Can Do" at: https://lnkd.in/eFHXh4jn VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to adult and pediatric patients globally. To learn more about our work in this area, please visit VIVUS.com. #treatingobesity #obesitymedicine #weightmanagement #weightlossmedications #vivusllc

We hope you have a happy Labor Day and can enjoy a well-deserved day off with family and friends! VIVUS will be closed on Monday, September 2nd, 2024. However, you can still find us online at VIVUS.com. #laborday2024 #vivusllc

Earlier this year, VIVUS celebrated our sales team driving exceptional results in 2023 at our National Sales Meeting in Tampa, Florida. We are grateful to have such a talented team of representatives and managers striving for strong results every day — while also demonstrating our values and commitment to improving patient quality of life. VIVUS is delighted to recognize our 2023 Circle of Excellence winners for their exceptional results. Congratulations to the following top performers: Scheri Fontenot, Caren Farrell, Edgar Ylagan, Susan Hrin-Loder, and Hillary Morabito. Great work team! Here’s to our continued success and growth in 2024! For more information about VIVUS and our commitment to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases please visit VIVUS.com.